Medline (NASDAQ:MDLN) Major Shareholder Private Ltd Gic Sells 271,994 Shares

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 271,994 shares of Medline stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02. Following the completion of the transaction, the insider owned 24,992,766 shares in the company, valued at approximately $882,994,422.78. This trade represents a 1.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total value of $70,367,600.80.

Medline Stock Performance

Shares of MDLN opened at $35.23 on Friday. Medline has a one year low of $32.81 and a one year high of $50.88. The company has a 50-day moving average of $38.22 and a two-hundred day moving average of $41.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.33 and a quick ratio of 2.51. The stock has a market cap of $46.28 billion and a price-to-earnings ratio of 110.09.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.32 by $0.18. The firm had revenue of $7.68 billion during the quarter. On average, equities research analysts expect that Medline will post 1.49 earnings per share for the current year.

Hedge Funds Weigh In On Medline

Several large investors have recently bought and sold shares of the business. Sound Income Strategies LLC bought a new position in Medline in the fourth quarter valued at approximately $25,000. Entrust Financial LLC acquired a new stake in Medline during the 4th quarter worth $26,000. GAMMA Investing LLC raised its position in shares of Medline by 68.3% during the 2nd quarter. GAMMA Investing LLC now owns 626 shares of the company’s stock valued at $25,000 after acquiring an additional 254 shares during the last quarter. NBC Securities Inc. acquired a new position in shares of Medline in the 4th quarter valued at $28,000. Finally, Whipplewood Advisors LLC bought a new position in shares of Medline in the 1st quarter worth $30,000.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
• Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
• Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
• Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Tigress Financial lifted their price objective on shares of Medline from $60.00 to $62.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. BNP Paribas Exane cut their price objective on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Sanford C. Bernstein reduced their price target on shares of Medline from $56.00 to $54.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Royal Bank Of Canada reduced their price objective on Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Weiss Ratings raised shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Medline presently has a consensus rating of “Moderate Buy” and an average target price of $48.50.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.